November, 2020
Safety and Efficacy of XMT-1536 in Ovarian Cancer: A Subgroup Analysis from the Phase 1 Expansion Study of XMT-1536, a NaPi2b Antibody-Drug Conjugate
September, 2020
Tumor Targeting of a STING Agonist by Means of an Antibody-Drug Conjugate Induces Potent Anti-Tumor Immune Responses
July, 2020
Systemic Administration of STING Agonist Antibody-Drug Conjugates Elicit Potent Anti-Tumor Immune Responses with Minimal Induction of Circulating Cytokines
June, 2020
XMT-1592, a Site-Specific Dolasynthen-Based NaPi2b-Targeted Antibody-Drug Conjugate for the Treatment of Ovarian Cancer and Lung Adenocarcinoma
June, 2020
Phase 1 expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC)
May, 2020
A Phase 1 study of XMT-1536 in patients with solid tumors likely to express NaPi2b: A summary of dose escalation
May, 2020
Tumor targeting of a STING agonist with an antibody drug conjugate elicits potent anti-tumor immune responses
November 2019
NaPi2b Expression in a Large Surgical Non-Small Cell Lung Cancer (NSCLC) Cohort
October 2019
Mersana’s Innovative ADC Platforms – World ADC Summit 2019
October 2019